Hyperpolarized 13C MR Imaging of Lactate in Patients With Locally Advanced Cervical Cancer (LACC) Cervical Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

November 13, 2017

Primary Completion Date

September 15, 2022

Study Completion Date

September 15, 2022

Conditions
Uterine Cervical Neoplasms
Interventions
DRUG

Hyperpolarized 13C-Pyruvate

The new imaging method being tested is called Metabolic MRI, which provides pictures of the metabolism occurring within cancer cells. It also involves injection of a contrast agent, Hyperpolarized Pyruvate (13C) Injection, into the arm vein. The participants will be injected with the study drug at a dose of 0.43 ml/kg and then receive a MRI scan.

DRUG

18F-FDG

18F-FDG is a radiopharmaceutical used in medical imaging. The uptake of 18F-FDG by tissues is a marker for the tissue uptake of glucose, which is correlated with certain types of tissue metabolism, particularly in cancer cells. The participant will be injected with the study drug at a dose of 5 MBq/kg to a maximum of 500 MBq and then receive a PET scan.

Trial Locations (1)

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

Sponsors
All Listed Sponsors
collaborator

Ontario Institute for Cancer Research

OTHER

lead

Sunnybrook Health Sciences Centre

OTHER